These are publications from work undertaken by Frontier Science (Scotland).

1 2 3 4 5 6
A Sonnenblick;  E. de Azambuja; D Agbor-Tarh; I Bradbury; C Campbell; Y Huang; AC Dueck; KI Pritchard; AC Wolff; C Jackisch; I Lang; M Untch; I Smith; F Boyle; B Xu; H Gomez; EA Perez; M. Piccart; H. A. Azim Jr;  2016

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial

Journal of the National Cancer Institute,  Volume 108, Issue 8, doi:10.1093/jnci/djw037

C. Criscitiello;  H. A. Azim Jr; D Agbor-Tarh; E. de Azambuja; M. Piccart; J Baselga; H. Eidtmann; S. Di Cosimo; I Bradbury; IT Rubio;  2013

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2- positive breast cancer: results from the NeoALTTO phase III trial

Annals of Oncology,  Volume 24, Issue No 8, Pages 1980-1985, doi:10.1093/annonc/mdt129

L. Zabaglo;  O. Stoss; J. Rüschoff; D. Zielinski; J Salter; M Arfi; I Bradbury; M Piccart-Gebhart; M Procter; M Dowsett;  2013

HER2 Staining Intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

Annals of Oncology,  Volume 24, Issue No 11, Pages 2761-2766, doi:10.1093/annonc/mdt275

1 2 3 4 5 6